Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment. ‐ 12 months · Adults with refractive errors
Wavefront‐optimized procedures showed no clear difference in proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or… compared with wavefront‐guided procedures (low certainty).
1 finding from 1 review
Loss of 1 or more lines of BSCVA at 12 months post treatment · Adults with refractive errors
Wavefront‐optimized procedures showed no clear difference in proportion of eyes that had lost 1 or more lines of best… compared with wavefront‐guided procedures (low certainty).
1 finding from 1 review
Cure · people who are being treated for active VL
1 finding from 1 review
Definitive cure · people who are being treated for active VL
1 finding from 1 review
Completion of treatment · people who are being treated for active VL
1 finding from 1 review
Resolution of symptoms · people who are being treated for active VL
1 finding from 1 review
Physical growth / weight gain · people who are being treated for active VL
1 finding from 1 review
Adverse outcomes · people who are being treated for active VL
1 finding from 1 review
Mortality (all‐cause) · people with cirrhosis and hepatorenal syndrome
It is very uncertain whether terlipressin changes mortality (All‐cause) compared with other vasoactive drugs (very low certainty).
1 finding from 1 review
RR 0.96 [0.88, 1.06]
474 participants
Very low
Hepatorenal syndrome (Number of participants who did not achieve reversal of hepatorenal syndrome) · people with cirrhosis and hepatorenal syndrome
It is very uncertain whether terlipressin changes hepatorenal syndrome (Number of participants who did not achieve… compared with other vasoactive drugs (very low certainty).
1 finding from 1 review
RR 0.79 [0.63, 0.99]
394 participants
Very low
Serious adverse events · people with cirrhosis and hepatorenal syndrome
It is very uncertain whether terlipressin changes serious adverse events compared with other vasoactive drugs (very low certainty).
1 finding from 1 review
RR 0.96 [0.88, 1.06]
474 participants
Very low
Non‐serious adverse events: diarrhoea or abdominal pain, or both · people with cirrhosis and hepatorenal syndrome
It is very uncertain whether terlipressin changes non‐serious adverse events: diarrhoea or abdominal pain, or both compared with other vasoactive drugs (very low certainty).
1 finding from 1 review
RR 3.5 [1.19, 10.27]
221 participants
Very low
Clinical cure: syndromic approach · sexually active adults
Macrolides showed no clear difference in clinical cure: syndromic approach compared with any other antibiotic (low certainty).
1 finding from 1 review
Clinical cure: aetiological approach · sexually active adults
Macrolides showed no clear difference in clinical cure: aetiological approach compared with any other antibiotic (low certainty).
1 finding from 1 review
Clinical improvement: syndromic approach · sexually active adults
It is very uncertain whether macrolides changes clinical improvement: syndromic approach compared with any other antibiotic (very low certainty).
1 finding from 1 review
Clinical improvement: aetiological approach · sexually active adults
Macrolides showed no clear difference in clinical improvement: aetiological approach compared with any other antibiotic (low certainty).
1 finding from 1 review
Microbiological cure · sexually active adults
Macrolides showed no clear difference in microbiological cure compared with any other antibiotic (low certainty).
1 finding from 1 review
Minor adverse events · sexually active adults
It is very uncertain whether macrolides changes minor adverse events compared with any other antibiotic (very low certainty).
1 finding from 1 review
Clinical cure: syndromic approach · sexually active adults
Macrolide (erythromycin) showed no clear difference in clinical cure: syndromic approach compared with any other macrolide (low certainty).
1 finding from 1 review
Clinical cure: aetiological approach · sexually active adults
Macrolide (erythromycin) showed no clear difference in clinical cure: aetiological approach compared with any other macrolide (low certainty).
1 finding from 1 review